Liquidia Technologies touted initial data from its LIQ865 Phase I trial, which evaluated its sustained-delivery formulation of bupivacaine for post-surgical pain relief.
The trial was the 1st evaluation of the company’s formulation in humans. Researchers assessed the safety, pharmacokinetic profile and pharmacodynamic response of a single-ascending dose in healthy adult males.
Get the full story at our sister site, Drug Delivery Business News.
The post Liquidia touts Phase I data for sustained-release post-surgical pain reliever appeared first on MassDevice.